Skip to content

Troponin in Acute Chest Pain to Risk Stratify and Guide EffecTive Use of Computed Tomography Coronary Angiography

Troponin in Acute Chest Pain to Risk Stratify and Guide EffecTive Use of Computed Tomography Coronary Angiography

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03952351
Acronym
TARGET-CTCA
Enrollment
3170
Registered
2019-05-16
Start date
2026-01-31
Completion date
2026-08-28
Last updated
2026-04-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Disease

Brief summary

Most patients presenting to hospital with symptoms of a heart attack are sent home without further tests once a heart attack has been ruled out. Current strategies to assess patients with a suspected heart attack involve blood tests to measure troponin, a protein released into the bloodstream when the heart muscle is damaged. Despite having had a heart attack ruled-out, some patients have unrecognised heart disease and are at risk of having a heart attack in the future. However, clinicians do not know what is the best approach to identify and treat these patients. This study will use a heart scan known as computed tomography coronary angiogram (CTCA) to look for unrecognised heart disease in patients who have had a heart attack ruled out. In an earlier study, the Investigators performed this scan in patients referred to the outpatient cardiology clinic with stable chest pain and found that this improved the diagnosis of heart disease, leading to improvement in patient care that prevented future heart attacks. Previous research from the Investigators has also found that troponin levels below those used to diagnose a heart attack may help to identify those who are at greater risk of having a heart attack in the future. The aim of this study is to find out if patients with these low levels of troponin, where a heart attack has been ruled out, will benefit from CTCA to look for unrecognised coronary heart disease.

Interventions

CTCA scan in accordance with British Society of Cardiovascular Imaging CT guidelines

Sponsors

University of Edinburgh
Lead SponsorOTHER
British Heart Foundation
CollaboratorOTHER
University of Sheffield
CollaboratorOTHER
NHS Lothian
CollaboratorOTHER_GOV
NHS Greater Glasgow and Clyde
CollaboratorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SCREENING
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Presenting to hospital with symptoms of suspected acute coronary syndrome * Age 18 years and over * Maximum high-sensitivity cardiac troponin concentration between 5ng/L and the 99th percentile

Exclusion criteria

* Diagnosis of myocardial infarction during index presentation * Clear alternative diagnosis or participant requires further inpatient clinical assessment * Recent CTCA or invasive coronary angiogram (within 1 year) * Patient inability to undergo CT scanning, e.g. due to severe renal failure (estimated glomerular filtration rate \<30 mL/min) or major allergy to iodinated contrast media * Current pregnancy or breast feeding * Inability to give informed consent * Further investigation for coronary artery disease would not be in the patient's interest, e.g. due to limited life expectancy, quality of life or functional status * Previous randomisation into the trial

Design outcomes

Primary

MeasureTime frameDescription
Composite of myocardial infarction or cardiac deathRandomisation through to study completion, median duration of 36 monthsThe first event of myocardial infarction or cardiac death

Secondary

MeasureTime frameDescription
Myocardial InfarctionRandomisation through to study completion, median duration of 36 monthsThe first event of myocardial infarction (MI). MI will be defined according to the 4th Universal Definition of Myocardial Infarction
Cardiac deathRandomisation through to study completion, median duration of 36 monthsCardiac death will be defined as death resulting from an acute myocardial infarction, sudden cardiac death, or death due to heart failure.
Cardiovascular deathRandomisation through to study completion, median duration of 36 monthsCardiovascular death will be defined as death resulting from an acute myocardial infarction, sudden cardiac death, death due to heart failure, death due to stroke, death due to cardiovascular haemorrhage, and death due to other cardiovascular causes
Non-cardiovascular deathRandomisation through to study completion, median duration of 36 months
All-cause deathRandomisation through to study completion, median duration of 36 months
Unscheduled urgent coronary revascularisationRandomisation through to study completion, median duration of 36 monthsUnscheduled urgent coronary revascularisation will be identified via record linkage from central NHS registers (e.g. the Scottish Morbidity Register by the Information Services Division (ISD) Scotland) or from extracts obtained from the participating hospitals electronic patient record system.
Hospital reattendance with suspected ACSRandomisation through to study completion, median duration of 36 monthsReattendance with suspected ACS will be defined as any unscheduled hospital attendance where cardiac troponin testing is performed for suspected ACS following randomisation
Proportion of patients with major bleeding (BARC 3-5)Randomisation through to study completion, median duration of 36 monthsBleeding will be defined according to the Bleeding Academic Research Consortium (BARC) definition of bleeding. We will use pre-defined codes from International Classification of Diseases (ICD-10) and Office of Population Censuses and Surveys (OPCS) to classify each bleeding event as per the BARC definition.
Symptomatic status as assessed by the short form Seattle Angina Questionnaire (SAQ-7)3, 12 and 24 months
Quality of life as assessed by the EQ-5D-5L3, 12 and 24 months

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 31, 2026